Ref ID: 17765
Author:
M. Hoenigl*, K. Seeber, R. Raggam, T. Valentin, A. Valentin,
A. Strohmeier, I. Zollner-Schwetz, A. Woelfler, A. Grisold, W. Linkesch,
R. Krause
Author address:
(Graz, AT)
Full conference title:
22nd European Congress of Clinical Microbiology and Infectious Diseases
Abstract:
Objective: Therapeutic drug monitoring (TDM) has shown useful for
oral antifungal agents in patients with hematologic malignancies. The
effect of introduction of TDM on prescribing praxis is unknown. We
evaluated the impact of posaconazole TDM on antifungal prophylaxis
and therapy.
Methods: Applied antifungal prophylaxis and therapy were assessed in
patients with underlying hematologic diseases by conducting a
prospective observational single-centre study at the Division of
Hematology, Medical University of Graz, Austria, for 7 months in
2010. To analyze the impact of PPC testing on antifungal prophylaxis
and therapy results obtained were compared to a representative
collective of patients assessed by the same investigators at the same
institution over 7 months in 2007 before testing of posaconazole plasma
concentrations (PPCs) has been introduced.
Results: In 2010, 129/729 (18%) of cases with hematologic
malignancies received systemic antifungal prophylaxis and therapy.
Of those, fifty-seven percent received prophylactic, 44% empiric, 30%
preemptive and 6% directed antifungal therapy. Main reasons for
prophylaxis were neutropenia in AML patients (40/74; 54%), followed
by GVHD (18/74; 24%) and allogeneic HSCT (16/74; 22%). Eleven
out of 39 (28%) cases receiving preemptive therapy had clinical/
radiological and microbiological evidence of IFI, 26/39 (67%) had
clinical/radiological and 2/39 (5%) only microbiological evidence of
Abstract Number: P857
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a